Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer
Authors
Keywords
Lung and intrathoracic tumors, Immunohistochemistry techniques, Biopsy, Small cell lung cancer, Carcinomas, Histology, Hematoxylin staining, Non-small cell lung cancer
Journal
PLoS One
Volume 12, Issue 10, Pages e0186192
Publisher
Public Library of Science (PLoS)
Online
2017-10-20
DOI
10.1371/journal.pone.0186192
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation
- (2017) Kenichi Suda et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy
- (2016) AS Mansfield et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy
- (2016) LC Villaruz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
- (2016) Junzo Hamanishi et al. International Journal of Clinical Oncology
- PD-L1 Expression in Lung Cancer
- (2016) Hui Yu et al. Journal of Thoracic Oncology
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
- (2016) Mari Mino-Kenudson et al. Cancer Biology & Medicine
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
- (2015) J.-C. Soria et al. CLINICAL CANCER RESEARCH
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- (2015) R. Katayama et al. CLINICAL CANCER RESEARCH
- Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer
- (2015) Satoru Kitazono et al. Clinical Lung Cancer
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
- (2015) Moon-Young Kim et al. LUNG CANCER
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
- (2015) Therese Phillips et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Establishing the Diagnosis of Lung Cancer
- (2013) M. Patricia Rivera et al. CHEST
- Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research
- (2013) AKIRA KOMIYA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
- (2013) William D. Travis et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Spiral Array: A New High-Throughput Technology Covers Tissue Heterogeneity
- (2012) Junya Fukuoka et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
- (2009) Akira Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started